FDA Extends Regulatory Review Period for IDegLira by Three Months

Bagsv ærd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news